These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20386075)

  • 1. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    Price H; Asboe D; Pozniak A; Gazzard B; Fearnhill E; Pillay D; Dunn D; ;
    Antivir Ther; 2010; 15(2):203-11. PubMed ID: 20386075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
    PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    Manasa J; Lessells RJ; Skingsley A; Naidu KK; Newell ML; McGrath N; de Oliveira T;
    PLoS One; 2013; 8(8):e72152. PubMed ID: 23991055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
    Tang MW; Rhee SY; Bertagnolio S; Ford N; Holmes S; Sigaloff KC; Hamers RL; de Wit TF; Fleury HJ; Kanki PJ; Ruxrungtham K; Hawkins CA; Wallis CL; Stevens W; van Zyl GU; Manosuthi W; Hosseinipour MC; Ngo-Giang-Huong N; Belec L; Peeters M; Aghokeng A; Bunupuradah T; Burda S; Cane P; Cappelli G; Charpentier C; Dagnra AY; Deshpande AK; El-Katib Z; Eshleman SH; Fokam J; Gody JC; Katzenstein D; Koyalta DD; Kumwenda JJ; Lallemant M; Lynen L; Marconi VC; Margot NA; Moussa S; Ndung'u T; Nyambi PN; Orrell C; Schapiro JM; Schuurman R; Sirivichayakul S; Smith D; Zolfo M; Jordan MR; Shafer RW
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S70-7. PubMed ID: 23687292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
    Yap SH; Herman BD; Radzio J; Sluis-Cremer N; Tachedjian G
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):153-7. PubMed ID: 22743599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
    Sluis-Cremer N; Moore K; Radzio J; Sonza S; Tachedjian G
    AIDS; 2010 Jan; 24(2):317-9. PubMed ID: 20010074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.
    McCormick AL; Parry CM; Crombe A; Goodall RL; Gupta RK; Kaleebu P; Kityo C; Chirara M; Towers GJ; Pillay D
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1806-9. PubMed ID: 21282419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    Nii-Trebi NI; Ibe S; Barnor JS; Ishikawa K; Brandful JA; Ofori SB; Yamaoka S; Ampofo WK; Sugiura W
    PLoS One; 2013; 8(8):e71972. PubMed ID: 23977189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
    Biondi MJ; Beilhartz GL; McCormick S; Götte M
    J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
    Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
    Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
    Waters JM; O'Neal W; White KL; Wakeford C; Lansdon EB; Harris J; Svarovskaia ES; Miller MD; Borroto-Esoda K
    Antivir Ther; 2009; 14(2):231-9. PubMed ID: 19430098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
    J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.